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Gilles de la Tourette’s syndrome, or Tourette’s syndrome, is a
neurodevelopmental condition characterised by multiple motor
and vocal tics, which appear in childhood and are often
accompanied by behavioural symptoms.1 Originally described
by French physician Georges Gilles de la Tourette in 1885,2 this
syndrome has long been considered a rare medical condition,
until large epidemiological studies showed that 0.3-1% of school
age children fulfil established diagnostic criteria for this
condition.3 4 In the United Kingdom, it is estimated that as many
as 200 000-330 000 people are affected, with different degrees
of severity.1 4 Although it is estimated that about two thirds of
patients with GTS improve by adulthood the syndrome affects
health related quality of life.5 This article reviews current
knowledge about the diagnosis and management of Tourette’s
syndrome, including drug treatments and behavioural
interventions.
What is Tourette’s syndrome and who
gets it?
The chronic presence of at least two motor tics and one vocal
tic since childhood is recognised as the key feature of Tourette’s
syndrome. Tics are defined as involuntary, sudden, rapid,
recurrent, non-rhythmic movements (motor tics) and
vocalisations (vocal or phonic tics). It is now known that the
syndrome occurs worldwide, across all races and ethnicities, in
both sexes (four times more prevalent in males than in females),
and in children as well as in adults, although the average age at
onset is around 6 years and adult onset of tics is rare.3
Motor tics generally precede the development of vocal tics, and
the onset of simple tics often predates that of complex tics.
Simple motor tics can manifest themselves as eye blinking,
facial grimacing, shoulder shrugging, neck stretching, and
abdominal contractions. The most common vocal tics are
sniffing, grunting, and throat clearing. Gilles de la Tourette’s
original case series described nine patients who also presented
with complex tics; namely, echolalia (repeating other people’s
words) and coprolalia (swearing as a tic).2 Both coprolalia and
copropraxia (involuntary production of rude gestures as complex
tics) are relatively rare, occurring in about 10% of patients
(20-30% in specialist clinics where more severe or complex
cases are seen).6
Both simple and complex tics are characteristically preceded
by a feeling of mounting inner tension, which is temporarily
relieved by tic expression.7 These sensations, also known as
“premonitory urges,” are a hallmark feature of tics, and they
enable clinicians to reliably distinguish Tourette’s syndrome
from other hyperkinetic movement disorders. However,
unequivocal reports of these sensations can prove difficult to
elicit in younger children.
Tic symptoms vary in frequency, severity, and distribution
throughout life. They have a waxing and waning course, usually
with a peak in severity during early teenage years. Although
large prognostic studies are lacking, clinical experience suggests
that in most cases tics improve or stabilise after puberty. Tics
tend to be exacerbated by anxiety and stress and alleviated by
mental and physical tasks that require concentration, such as
playing sports and music. Moreover, patients can voluntarily
suppress their tics for short periods (usually seconds to minutes),
at the expense of mounting inner tension and subsequent
rebound in tic severity. This feature is particularly relevant for
diagnostic purposes. Over the past few years, clinical studies
on social cognition have shown that certain social situations
and interactions with other people can play a central role in
modulating tic symptoms, including the expression of socially
inappropriate behaviours.8
Patients present with a wide range of tic severity, from mild
symptoms that do not cause serious impairment and often go
unnoticed, to loud noises and forceful movements that can result
in self injury. Owing to the potentially disabling nature of the
physical symptoms, some patients face problems with daily
activities, above and beyond those caused by the social stigma
associated with the disorder. The syndrome is not associated
with intellectual disability, and patients can be talented people
who achieve and often excel in different areas of life.
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Tourette’s syndrome is a tic disorder that is often associated with behavioural symptoms
Diagnostic criteria are based on the presence of both motor and vocal tics; because of its varied presentations, the syndrome has the
potential to be misdiagnosed
Prevalence is higher than commonly assumed; coprolalia is relatively rare (10-30%) and not required for diagnosis
The syndrome can cause serious distress and compromise health related quality of life
The main management strategies include psychoeducation, behavioural techniques, and drugs
Service provision is patchy even in developed countries and patients of all ages often “fall through the net” between neurology and
psychiatry
Sources and selection criteria
We based this review on articles found by searching Medline, the Cochrane Collaboration Library, Clinical Evidence, and the National Institute
for Health and Care Excellence website with the term “Tourette”. Our search was limited to English language articles published between
2005 and 2012. We also used evidence from published studies and guidelines on the management and treatment of Tourette’s syndrome
by the European Society for the Study of Tourette Syndrome and the Movement Disorders Society taskforces. Priority was given to evidence
obtained from systematic literature reviews, meta-analyses, and randomised controlled trials when possible.
How is Tourette’s syndrome diagnosed?
The diagnosis is clinical and relies on skilful observation and
comprehensive history taking. Updated diagnostic criteria for
tic disorders, including Tourette’s syndrome, have recently been
published in the Diagnostic and Statistical Manual of Mental
Disorders, fifth edition (box).9 The complex symptoms that
were originally described by Gilles de la Tourette (such as
coprolalia and echolalia) are not included in the diagnostic
criteria, which do not distinguish between simple and complex
tics. The differential diagnosis of tics includes myoclonic jerks,
mannerisms, and stereotypies (especially in the context of
autistic spectrum disorders), in addition to other hyperkinetic
movement disorders with onset in childhood. Specific
investigations, including laboratory tests and neuroimaging, are
indicated only to rule out other possible causes of tics in patients
with atypical presentations, which include acute onset, onset in
adulthood, or sustained/dystonic tics.
Does Tourette’s syndrome occur with
other disorders?
Most patients with Tourette’s syndrome also have specific
behavioural symptoms, which can complicate the clinical picture
considerably. Converging evidence from large clinical studies
conducted in specialist clinics,10 11 and in the community,12
indicates that only 10% of patients have no associated
psychiatric comorbidity (pure Tourette’s syndrome).
Consequently, the behavioural spectrum of the condition is
multifaceted (figure⇓) and the management of patients with
“Tourette’s syndrome plus” can pose considerable challenges
even to experienced clinicians. Obsessive-compulsive disorders
and attention-deficit/hyperactivity disorder (ADHD) are the
most common comorbidities, with an estimated prevalence of
around 60%.6 Interestingly, the obsessive-compulsive disorder
symptoms associated with tics overlap only partially with the
clinical presentation of patients with primary
obsessive-compulsive disorder. For instance, patients with
Tourette’s syndrome report a significantly higher prevalence of
concerns about symmetry, “evening-up” behaviours, obsessional
counting (arithmomania), and “just right” perceptions, whereas
patients with pure obsessive-compulsive disorder have a higher
rate of cleaning rituals, compulsive washing, and fears of
contamination.13These differences probably result from different
pathophysiological mechanisms, because only certain
obsessive-compulsive disorder symptoms are considered
intrinsic to Tourette’s syndrome. Similarly, some complex tics
can be misdiagnosed as compulsions, possibly leading to
overdiagnosis of comorbid obsessive-compulsive disorder, as
it seems to be suggested by the results of recent epidemiological
studies.4
The high prevalence of comorbidity between Tourette’s
syndrome and ADHD complicates the diagnosis and
management of children and adolescents with the syndrome.
By definition, tics involve hyperactivity and the constant effort
to suppress them can interfere with the ability to concentrate at
school. The diagnosis of comorbid ADHD should therefore be
established by experienced child and adolescent psychiatrists,
paediatricians, or adult psychiatrists or neuropsychiatrists after
a comprehensive clinical assessment. The decision of whether
to prioritise treatment of ADHD or tic symptoms is not easy,
because psychostimulants used to treat ADHD can increase tic
severity. Over the past few years, experts have reached an
evidence based consensus that patients with tics should be
treated with psychostimulants if the ADHD symptoms seriously
impair their quality of life. Particular attention to adequate
titration and avoidance of supratherapeutic doses is required.14
Tourette’s syndrome can lead to the development of affective
disorders through several mechanisms.15 Firstly, depression can
be an understandable psychological reaction to living with a
potentially disabling condition and its serious social stigma;
secondly, the multiple neurotransmitter abnormalities in
corticostriatal systems responsible for the involuntary
movements (tics) may also account for the impairment in
affective tone; finally, certain drugs commonly used to manage
tics (especially antidopaminergic agents) can cause depression.
Importantly, tics and Tourette’s syndrome are also more
common in patients with autistic spectrum disorders, and recent
studies found a significant association between Tourette’s
syndrome and impulse control disorders in adults (especially
intermittent explosive disorder),16 which can have relevant
medico-legal implications.17 Finally, the association with
personality disorders, which are over-represented in patients
with Tourette’s syndrome, especially those with comorbid
psychiatric disorders, requires further investigation.18
What impact does Tourette’s syndrome
have on health?
Over the past decade, there has been increased interest in the
assessment of the impact of Tourette’s syndrome on health
related quality of life. A controlled study that used generic
quality of life rating instruments demonstrated decreased quality
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Current diagnostic criteria for Tourette’s syndrome9
• At least two motor and one vocal tic (not necessarily concurrently)
• Presence of tics for at least 12 months
• Onset before age 18 years
• Tics not caused by the physiological effects of substances (such as stimulants) or other medical conditions (such as Huntington’s
disease)
of life.19Of note, the associated behavioural comorbidities often
compromise overall wellbeing much more than tic severity.
This observation is reflected in the multidimensional structure
of the only disease specific quality of life scale for Tourette’s
syndrome, which encompasses four domains: physical,
psychological, obsessional, and cognitive.20
What causes Tourette’s syndrome?
Little is known about the exact brain mechanisms associated
with tic development and expression, although preliminary
evidence from neurochemical and neuroimaging investigations
suggests a primary role for dysfunction of the dopaminergic
pathways within the cortico-striato-cortico-frontal circuitry.21
Neuropathological studies of patients with Tourette’s syndrome
are rare, but a few studies have provided evidence for deficits
in cerebral maturation, in particular at the level of striatal
interneurone migration.21 Genetic predisposition has a major
role in the development of the syndrome, as shown by early
family studies. Although segregation analyses of large kindreds
with multiple affected generations initially suggested an
autosomal dominant transmission model, polygenic and bilineal
transmission were also postulated, and subsequent investigations
found that the syndrome is a genetically heterogeneous
disorder.22
Findings from epidemiological and laboratory studies have also
drawn attention to the role of environmental factors, including
infections and autoimmune dysfunction, as well as prenatal and
perinatal problems, in at least a subset of patients. The
hypothesis that Tourette’s syndrome can be subsumed in a group
of conditions called paediatric autoimmune neuropsychiatric
disorders associated with streptococcal infections is still
controversial and requires further investigations.23 The concepts
of genetic and aetiological heterogeneity are in line with recent
clinical phenomenology studies, which confirmed the existence
of multiple phenotypes within the disease spectrum by using
principal component factor analysis and hierarchical cluster
analysis.6
Whom should I refer to a specialist?
Patients with suspected Tourette’s syndrome should be referred
to a specialist clinic, often part of a wider neuropsychiatric
service, where multidisciplinary input can be provided. Because
such clinics are few and far between, GPs can initially refer
younger patients to local child and adolescent mental health
services or community paediatrics services for a general
neurodevelopmental and behavioural assessment. Specialist
clinics could then be involved if the diagnosis is uncertain (for
example, when comorbidities are present) or to deliver specific
treatments. In adults, the pathway would be from primary care
to adult neurology or neuropsychiatry. Once the diagnosis is
established, patients should be reviewed at least once a year by
a clinician with knowledge about the complexities of the
disorder and its evolving treatment. Specialist services for these
patients are in great demand because this fascinating area of
neuropsychiatric medicine is underdeveloped in the UK.
How is Tourette’s syndrome managed?
Tourette’s syndrome is a lifelong condition with far reaching
implications. Relevant and accurate information, alongside
reassurance and explanation, should be provided to the patient,
relatives, teachers, employers, and medical professionals
involved. It is important to highlight that the syndrome is
compatible with success at school and in the workplace.
However, schools should be encouraged to implement
appropriate arrangements for affected children, and career
choices should take account of the practical implications of
having tics and behavioural symptoms. The European Society
for the Study of Tourette Syndrome recently published the first
European assessment andmanagement guidelines, which cover
behavioural interventions, drug treatment, and surgical options
for severe treatment refractory cases.24-28
What behavioural treatments are
available?
Awide range of behavioural interventions have been developed
or adapted to help patients maximise tic control.29Habit reversal
training or exposure and response prevention seem to be the
most promising approaches. These methods aim to enable
patients to recognise premonitory urges andmodify the response
to their occurrence, so that tic expression is delayed and
eventually abolished. Recently, two large randomised controlled
trials in children and adolescents30 and adults31 with Tourette’s
syndrome or chronic tic disorders found that a comprehensive
behavioural intervention for tics that incorporated habit reversal
training significantly reduced tic severity in about half of the
patients. Motivation to engage in the therapy sessions and full
awareness of the premonitory urge are important factors that
can increase response rate. In addition to enhancing tic
suppression, psychological interventions can improve patients’
awareness of the environmental factors that affect their tic
severity and can provide valuable support and skills to deal with
tic associated behavioural symptoms. Access to behavioural
treatment is currently limited even in developed countries. In
the future, telemedicine or remote consultations might widen
access to specialist diagnostic and therapy services.
When should drugs be prescribed?
Drugs should be considered in specialist settings, in addition to
psychoeducation and as an alternative or add-on to behavioural
therapy for patients whose tics are associated with clear
impairment. The European Society for the Study of Tourette
Syndrome recently published expert consensus on indications
for drug treatment. These included tics that cause subjective
discomfort (such as pain or injury), sustained social problems
(such as social isolation or bullying), social and emotional
problems (such as reactive depressive symptoms), or functional
interference (such as impairment of academic achievements).26
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Which drugs are effective?
Few double blind randomised controlled trials have been
conducted to test the efficacy of drugs for tic management,
especially newer ones, for which recommendations are based
on case series and open label trials.32 33 The first drugs to show
effectiveness in tic control were neuroleptics, especially
haloperidol and pimozide. These are still considered among the
most effective tic suppressants, and in many countries they are
the only drugs licensed for Tourette’s syndrome, based on
multiple randomised controlled trials. However, their poor
tolerability profile, mainly due to extrapyramidal and metabolic
side effects, restricts their use to second line or third line options,
and only in selected patients.
Over the past couple of decades these drugs have been replaced
by the newer antidopaminergic agents—the atypical
antipsychotics—which are better tolerated overall and have
similar efficacy for tic control. Within this group, there are
positive data from randomised controlled studies for risperidone
and promising findings from open label studies for aripiprazole,
which has the best tolerability profile thanks to its partial
dopamine agonist action. Aripiprazole has led to tic reduction
in 65-85% of patients treated in open label trials, whereas rates
of discontinuation due to adverse effects have been lower than
25%.26 Substitute benzamides (such as sulpiride) and presynaptic
dopamine depletors (such as tetrabenazine) offer valuable
alternatives, although both these drug classes and the newer
antipsychotics can still have serious metabolic side effects,
especially hyperprolactinaemia and weight gain. Importantly,
antidopaminergic agents can also be useful as augmentation
therapy in patients treated with selective serotonin reuptake
inhibitors or serotonergic agents because of severe comorbid
obsessive-compulsive disorder.
Centrally acting α2 adrenergic agonists, such as clonidine and
guanfacine, can be considered as first line treatment for young
patients, because they have fewer adverse effects than other
classes and their antinoradrenergic action can also be effective
for comorbid ADHD. Evidence of efficacy against tics is also
robust (randomised placebo controlled double blind trials), and
mild side effects related to their hypotensive action should be
monitored.33 Benzodiazepines should be avoided for the long
term management of tics because of addiction and tolerance.
However, positive results from open label and double blind
controlled trials indicate that other agents that enhance
γ-aminobutyric acid (GABA) activity, particularly antiepileptic
drugs such as topiramate, have shown some benefit in small
open label and double blind controlled trials, although further
studies are needed to confirm this.26 Likewise, preliminary
evidence for tic suppressing properties from controlled trials on
Δ9-tetrahydrocannabinol should prompt further investigations
on the efficacy and tolerability of purified cannabinoids,
especially in adults who are refractory to treatment.26 Despite
the paucity of evidence based data, the recently published
European guidelines offer useful treatment algorithms based on
the consensus of a large number of experts.26
Is there any other treatment?
Botulinum toxin injections are indicated for the symptomatic
treatment of isolated tics (including vocal tics), with positive
results from open label studies, especially in patients with focal
dystonic tics.26 Finally, a few selected patients with severe tics
who do not respond to conventional interventions might be
considered for surgery.28 The first patient with Tourette’s
syndrome who successfully underwent the functional
neurosurgical procedure of thalamic deep brain stimulation was
reported in 1999.34 Since then, more than 100 procedures have
been reported, mainly single case reports and small case series,
with varying degrees of success.35 There is therefore little
evidence on which surgeons can determine the suitability of a
candidate and the optimal brain target because deep brain
stimulation of the globus pallidus-pars interna and thalamic
ventromedian-parafascicular nucleus often yield similar results
in terms of efficacy, with the first option showing a better side
effect profile. Currently, this procedure is still considered as a
last resort and is rarely recommended.
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Tips for non-specialists
Tics are not just habits and should not be ignored if they cause distress
Tics tend to run in families and can be motor or vocal-phonic
Involuntary swearing is a socially disabling tic symptom that is present in only 10-30% of patients with Tourette’s syndrome
The presence of comorbid behavioural symptoms often makes the diagnosis more difficult
Multidisciplinary care within specialist settings is recommended when the clinical picture is unclear, complex, or challenging
Offer psychoeducation and discuss behavioural and drug treatments with patients
Refer patients to useful sources of information, such as the Tourettes Action or Tourette Syndrome Association’s websites
Additional educational resources
Resources for healthcare professionals
BMJ Best Practice (http://bestpractice.bmj.com/best-practice/monograph/1042.html)—Useful best practice module on Tourette’s syndrome
Martino D, Leckman JF, eds. Tourette syndrome. Oxford University Press, 2013. Multi-authored textbook covering all aspects of the
condition from a large group of experts
Robertson MM, Cavanna AE. Tourette syndrome: the facts. Oxford University Press, 2008. Concise reference that provides an evidence
based overview
Movement Disorders Society (www.movementdisorders.org)—Main international society dedicated to the research and care of patients
with movement disorders, including Tourette’s syndrome
European Multicentre Study on Tics (www.emtics.eu)—First large-scale European collaborative study on Tourette syndrome
Resources for patients
Tourette’s syndrome: NHS choices (www.nhs.uk/Conditions/Tourette-syndrome/Pages/Introduction.aspx)—NHS website that provides
advice on Tourette’s syndrome, how it is diagnosed, and common treatments
European Society for the Study of Tourette Syndrome (http://tourette-eu.org/)—European collaborative website that provides support
and advice for patients
Tourette Syndrome Association (www.tsa-usa.org)—US based charity providing information about the condition and ongoing research
Tourettes Action (www.tourettes-action.org.uk)—UK based organisation providing information and support to patients
Questions for future research
What factors trigger the waxing of tics and how can waxing episodes be recognised earlier and prevented?
What behavioural symptoms are integral to Tourette’s syndrome?
What are the different clinical phenotypes of the syndrome?
What is the relative contribution of genetic and environmental factors in the development of this syndrome?
Which is the primary brain pathophysiological process?
How can we define treatment refractoriness in this syndrome?
Is deep brain stimulation a feasible treatment option and for whom?
Is behaviour therapy as effective as drugs, and is the combination of the two treatments more effective than either one alone?
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Figure
Schematic representation of the behavioural spectrum in Tourette’s syndrome: the size of each area is proportional to the
estimated prevalence of the symptoms; the background colour intensity is proportional to the complexity of the clinical
presentation
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